Therapeuticsmd Inc (TXMD)

$1.12 -0.07 (-5.88%)
Market Cap 13.66M
Revenue (ttm) 1.76M
Net Income (ttm) -2.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -123.86%
Debt to Equity Ratio 0.00
Volume 57,247
Avg Vol 51,528
Day's Range N/A - N/A
Shares Out 11.57M
Stochastic %K 75%
Beta 0.65
Analysts Strong Buy
Price Target $5.00

Company Profile

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 561 961 1900
Address:
951 Yamato Road, Suite 220, Boca Raton, United States
jfer333
jfer333 Jun. 26 at 1:54 AM
$TXMD ♟️ Rubric’s Presence = Financial Firepower + Legal Leverage Here’s what Rubric being officially disclosed as TXMD’s “corporate parent” signals: Rubric’s official presence gives TXMD: • Credibility • Legal staying power • Negotiation leverage • A more attractive litigation position if Mayne considers settlement or further asset moves This turns TXMD from a struggling company into a formidable litigation entity backed by institutional muscle.
0 · Reply
Bio_Invest101
Bio_Invest101 Jun. 23 at 11:14 PM
$TXMD IBO did a reverse merger and went up 344% today If Rubric missed last BO at $10 and could not get us $5 this time from any buyers then no point to drag further into legal fights with Wayne. https://www.globenewswire.com/news-release/2025/06/23/3103299/0/en/Dr-Ashleys-Limited-and-Impact-BioMedical-Inc-Announce-Strategic-Merger.html Dr Ashleys Limited and Impact BioMedical Inc. Announce
1 · Reply
h8ster
h8ster Jun. 20 at 7:29 PM
$TXMD Its going to be interesting to see how the courts decipher Rubric Capital's involvement here. Rubric is heavily invested in both TXMD and Mayne Pharma. Enough so in TXMD that they are TXMD's 'Parent' company. And their investment in Mayne Pamra, being a $27.95M convertible note which helped enable Mayne to license TXMD's products, as part of the $153M deal. A convertible note is essentially a loan, which the amount can be converted into shares, at an agreed price, rather a cash repayment. With the BO, Rubric stood to make a sizable fortune on the premium offered by Cosette, that being $7.40 per Mayne share. So why is TXMD throwing wrenches into the gears of this BO? Or maybe they suspected ahead of time that the Cosette deal was going to fall apart and got ahead of things with the lawsuit.
2 · Reply
ekraus
ekraus Jun. 20 at 5:23 AM
$TXMD well pain is enjotable to some
0 · Reply
h8ster
h8ster Jun. 19 at 4:17 AM
$TXMD Update in the Mayne vs TXMD case. TXMD has asked for an extension to give their response to Mayne's complaint against them. Its is scheduled for June 24. TXMD wants it extended to July 28th. Also filed by TXMD is the listing of Rubric Capital as their parent company.
2 · Reply
h8ster
h8ster Jun. 18 at 5:07 PM
$TXMD Mayne voters have approved the buyout from Cosette. Now, they have to force Cosette into holding up the deal. "Subject to Mayne Pharma successfully challenging Cosette’s purported termination of the Scheme Implementation Deed, Mayne Pharma will seek orders from the Supreme Court of New South Wales for the approval of the Scheme at the Second Court Hearing, currently scheduled for 9:15am (Sydney time) on Thursday, 18 September 2025."
0 · Reply
Plain360
Plain360 Jun. 17 at 11:22 PM
$JBIO, $NAK, $INDO, $PHGE and $HCTI are my green winners, pumped $PCSA , made some coin on $AZTR $SOND $BATL had these losers but only a few coins $ZBAI lost 8.00 $TXMD lost 3.00 still sitting on 10 put options for $WOLF exp in Sep at 7.00 (have these potatos since early march held too long and the WSJ article made me a loser.
0 · Reply
jfer333
jfer333 Jun. 17 at 7:50 PM
$TXMD let’s see Cosette acquire TXMD before Sept 9. If Cosette Pharmaceuticals were to acquire TherapeuticsMD, it could significantly escalate pressure on Mayne Pharma—here’s how that would likely play out: 🔍 1 Of 3: Cosette Would Inherit the Lawsuit If Cosette buys TherapeuticsMD, they would inherit any ongoing legal actions TherapeuticsMD is pursuing—including the one against Mayne Pharma. This would consolidate Cosette’s legal leverage over Mayne. Instead of fighting two opponents separately, Mayne would now be facing a united, better-resourced adversary.
1 · Reply
ekraus
ekraus Jun. 17 at 6:46 PM
$TXMD bummer went way up, just to collapse again dang ghat must feel awful
3 · Reply
h8ster
h8ster Jun. 17 at 5:29 PM
$TXMD Update on the TXMD vs Mayne lawsuit. TXMD has asked for an extension of time to respond to Mayne. see attachment for related info.
1 · Reply
Latest News on TXMD
TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 6 weeks ago

TherapeuticsMD Announces First Quarter 2025 Financial Results

TherapeuticsMD Announces Full Year 2024 Financial Results

Mar 27, 2025, 4:05 PM EDT - 3 months ago

TherapeuticsMD Announces Full Year 2024 Financial Results

TherapeuticsMD Announces Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 8 months ago

TherapeuticsMD Announces Third Quarter 2024 Financial Results

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

Aug 26, 2024, 7:36 AM EDT - 10 months ago

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

TherapeuticsMD Announces Second Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 11 months ago

TherapeuticsMD Announces Second Quarter 2024 Financial Results

TherapeuticsMD Announces First Quarter 2024 Financial Results

May 10, 2024, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces First Quarter 2024 Financial Results

TherapeuticsMD Announces Full Year 2023 Financial Results

Mar 29, 2024, 4:00 PM EDT - 1 year ago

TherapeuticsMD Announces Full Year 2023 Financial Results

TherapeuticsMD Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 1 year ago

TherapeuticsMD Announces Third Quarter 2023 Financial Results

TherapeuticsMD Announces Second Quarter 2023 Financial Results

Aug 14, 2023, 6:50 AM EDT - 2 years ago

TherapeuticsMD Announces Second Quarter 2023 Financial Results

TherapeuticsMD: From Fallen And Forgotten To Cash Cow

May 23, 2023, 9:00 AM EDT - 2 years ago

TherapeuticsMD: From Fallen And Forgotten To Cash Cow

TherapeuticsMD Announces First Quarter 2023 Financial Results

May 15, 2023, 4:05 PM EDT - 2 years ago

TherapeuticsMD Announces First Quarter 2023 Financial Results

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

Apr 7, 2023, 4:01 PM EDT - 2 years ago

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

Jan 3, 2023, 6:50 AM EST - 2 years ago

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Dec 4, 2022, 6:00 PM EST - 2 years ago

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD Announces Third Quarter 2022 Financial Results

Nov 14, 2022, 4:05 PM EST - 2 years ago

TherapeuticsMD Announces Third Quarter 2022 Financial Results

TherapeuticsMD Announces Additional $7 Million Private Placement

Oct 31, 2022, 6:50 AM EDT - 2 years ago

TherapeuticsMD Announces Additional $7 Million Private Placement

TherapeuticsMD Announces $7 Million Private Placement

Oct 3, 2022, 6:50 AM EDT - 2 years ago

TherapeuticsMD Announces $7 Million Private Placement

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

Sep 12, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript

Aug 15, 2022, 9:46 AM EDT - 3 years ago

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Aug 15, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces Second Quarter 2022 Financial Results

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 8, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Aug 1, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Why TherapeuticsMD Shares Are Sinking Today?

Jul 13, 2022, 9:59 AM EDT - 3 years ago

Why TherapeuticsMD Shares Are Sinking Today?

TherapeuticsMD's stock falls 41% after tender offer expires

Jul 13, 2022, 8:25 AM EDT - 3 years ago

TherapeuticsMD's stock falls 41% after tender offer expires

TherapeuticsMD Announces Expiration of Tender Offer

Jul 13, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces Expiration of Tender Offer

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

Jul 6, 2022, 6:09 AM EDT - 3 years ago

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Jun 21, 2022, 12:01 PM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

WEBR

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Jun 16, 2022, 2:43 PM EDT - 3 years ago

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

Jun 13, 2022, 10:49 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

BEEM

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

Jun 6, 2022, 4:05 PM EDT - 3 years ago

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

May 31, 2022, 7:34 PM EDT - 3 years ago

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

Here is why TherapeuticsMD jumped 300%

May 31, 2022, 1:57 PM EDT - 3 years ago

Here is why TherapeuticsMD jumped 300%

Why TherapeuticsMD Stock Is Soaring Today

May 31, 2022, 10:12 AM EDT - 3 years ago

Why TherapeuticsMD Stock Is Soaring Today

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

May 31, 2022, 6:00 AM EDT - 3 years ago

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

Why TherapeuticsMD Shares Are Trading Higher Today

May 20, 2022, 10:54 AM EDT - 3 years ago

Why TherapeuticsMD Shares Are Trading Higher Today

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

May 20, 2022, 9:43 AM EDT - 3 years ago

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 8:07 PM EDT - 3 years ago

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q1 2022 Results - Earnings Call Transcript

TherapeuticsMD Announces First Quarter 2022 Financial Results

May 16, 2022, 4:05 PM EDT - 3 years ago

TherapeuticsMD Announces First Quarter 2022 Financial Results

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

May 10, 2022, 4:05 PM EDT - 3 years ago

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

Apr 14, 2022, 4:15 PM EDT - 3 years ago

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

GDRX

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Mar 14, 2022, 8:39 AM EDT - 3 years ago

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd On Q4 2021 Results - Earnings Call Transcript

Mar 10, 2022, 10:35 AM EST - 3 years ago

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd On Q4 2021 Results - Earnings Call Transcript

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Mar 10, 2022, 6:50 AM EST - 3 years ago

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Why TherapeuticsMD Shares Are Soaring Today

Mar 7, 2022, 9:38 AM EST - 3 years ago

Why TherapeuticsMD Shares Are Soaring Today

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

Mar 7, 2022, 7:57 AM EST - 3 years ago

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

Mar 7, 2022, 7:40 AM EST - 3 years ago

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

GDRX

jfer333
jfer333 Jun. 26 at 1:54 AM
$TXMD ♟️ Rubric’s Presence = Financial Firepower + Legal Leverage Here’s what Rubric being officially disclosed as TXMD’s “corporate parent” signals: Rubric’s official presence gives TXMD: • Credibility • Legal staying power • Negotiation leverage • A more attractive litigation position if Mayne considers settlement or further asset moves This turns TXMD from a struggling company into a formidable litigation entity backed by institutional muscle.
0 · Reply
Bio_Invest101
Bio_Invest101 Jun. 23 at 11:14 PM
$TXMD IBO did a reverse merger and went up 344% today If Rubric missed last BO at $10 and could not get us $5 this time from any buyers then no point to drag further into legal fights with Wayne. https://www.globenewswire.com/news-release/2025/06/23/3103299/0/en/Dr-Ashleys-Limited-and-Impact-BioMedical-Inc-Announce-Strategic-Merger.html Dr Ashleys Limited and Impact BioMedical Inc. Announce
1 · Reply
h8ster
h8ster Jun. 20 at 7:29 PM
$TXMD Its going to be interesting to see how the courts decipher Rubric Capital's involvement here. Rubric is heavily invested in both TXMD and Mayne Pharma. Enough so in TXMD that they are TXMD's 'Parent' company. And their investment in Mayne Pamra, being a $27.95M convertible note which helped enable Mayne to license TXMD's products, as part of the $153M deal. A convertible note is essentially a loan, which the amount can be converted into shares, at an agreed price, rather a cash repayment. With the BO, Rubric stood to make a sizable fortune on the premium offered by Cosette, that being $7.40 per Mayne share. So why is TXMD throwing wrenches into the gears of this BO? Or maybe they suspected ahead of time that the Cosette deal was going to fall apart and got ahead of things with the lawsuit.
2 · Reply
ekraus
ekraus Jun. 20 at 5:23 AM
$TXMD well pain is enjotable to some
0 · Reply
h8ster
h8ster Jun. 19 at 4:17 AM
$TXMD Update in the Mayne vs TXMD case. TXMD has asked for an extension to give their response to Mayne's complaint against them. Its is scheduled for June 24. TXMD wants it extended to July 28th. Also filed by TXMD is the listing of Rubric Capital as their parent company.
2 · Reply
h8ster
h8ster Jun. 18 at 5:07 PM
$TXMD Mayne voters have approved the buyout from Cosette. Now, they have to force Cosette into holding up the deal. "Subject to Mayne Pharma successfully challenging Cosette’s purported termination of the Scheme Implementation Deed, Mayne Pharma will seek orders from the Supreme Court of New South Wales for the approval of the Scheme at the Second Court Hearing, currently scheduled for 9:15am (Sydney time) on Thursday, 18 September 2025."
0 · Reply
Plain360
Plain360 Jun. 17 at 11:22 PM
$JBIO, $NAK, $INDO, $PHGE and $HCTI are my green winners, pumped $PCSA , made some coin on $AZTR $SOND $BATL had these losers but only a few coins $ZBAI lost 8.00 $TXMD lost 3.00 still sitting on 10 put options for $WOLF exp in Sep at 7.00 (have these potatos since early march held too long and the WSJ article made me a loser.
0 · Reply
jfer333
jfer333 Jun. 17 at 7:50 PM
$TXMD let’s see Cosette acquire TXMD before Sept 9. If Cosette Pharmaceuticals were to acquire TherapeuticsMD, it could significantly escalate pressure on Mayne Pharma—here’s how that would likely play out: 🔍 1 Of 3: Cosette Would Inherit the Lawsuit If Cosette buys TherapeuticsMD, they would inherit any ongoing legal actions TherapeuticsMD is pursuing—including the one against Mayne Pharma. This would consolidate Cosette’s legal leverage over Mayne. Instead of fighting two opponents separately, Mayne would now be facing a united, better-resourced adversary.
1 · Reply
ekraus
ekraus Jun. 17 at 6:46 PM
$TXMD bummer went way up, just to collapse again dang ghat must feel awful
3 · Reply
h8ster
h8ster Jun. 17 at 5:29 PM
$TXMD Update on the TXMD vs Mayne lawsuit. TXMD has asked for an extension of time to respond to Mayne. see attachment for related info.
1 · Reply
h8ster
h8ster Jun. 16 at 5:52 PM
$TXMD Mayne Pharma and Cosette have agreed on a court timetable, with a hearing scheduled to begin on 9 September 2025. The Scheme Meeting for investors to vote on the BO deal remains scheduled for 18 June 2025. As for TXMD's lawsuit against Mayne, nothing has been publicly filed by the court clerk yet. TXMD's response to Mayne's claims was required last Friday. Should be available later today. As for Mayne's counter lawsuit against TXMD, there is nothing new or expected. Still going through the opening administrative phases.
2 · Reply
Jharding92
Jharding92 Jun. 16 at 1:26 PM
$TXMD https://yourir.info/resources/1d16bcfaddf9258f/announcements/myx.asx/3A669935/MYX_Update_on_litigation_with_Cosette.pdf?download=1
0 · Reply
h8ster
h8ster Jun. 13 at 5:29 PM
$TXMD Update #2. TXMD, at some point today will file its response to Mayne's motion to dismiss AND OR the court will answer Mayne's motion to dismiss and have the case go through mediation and be settled outside the courts. Will probably be posted mid-afternoon.
0 · Reply
h8ster
h8ster Jun. 13 at 5:22 PM
$TXMD New update from Mayne today. It addresses a second attempt by Cosette Pharmaceuticals to terminate the SID, which Mayne Pharma deems invalid. The company is taking legal action to enforce the SID and is telling shareholders to vote for the buyout at the Scheme Meeting, on June 18. Basically, Mayne is now in lawsuits with TXMD and Cosette.
0 · Reply
Jharding92
Jharding92 Jun. 13 at 12:54 PM
$TXMD https://yourir.info/resources/1d16bcfaddf9258f/announcements/myx.asx/3A669899/MYX_MYX_receives_further_purported_notice_to_terminate_SID.pdf?download=1
0 · Reply
YPOJOB
YPOJOB Jun. 13 at 11:51 AM
$TXMD Mayne Pharma is navigating a complex landscape with the TherapeuticsMD lawsuit, alleging fraud and breach of contract over a 2023 $153 million deal, seeking $11.5 million in damages. TherapeuticsMD’s counterclaims and Mayne’s motion to dismiss indicate a contentious legal battle. Concurrently, Mayne Pharma faces challenges with the Cosette acquisition, FDA scrutiny, and mixed shareholder movements, though revenue growth and new licensing deals show resilience. The shareholder meeting on June 18, 2025, will be critical for the Cosette deal, and the TherapeuticsMD litigation remains a key risk factor.
0 · Reply
Watchmeplz
Watchmeplz Jun. 12 at 3:12 PM
$SJM pump it up!!!!! $ON $TXMD $OXY $BA
0 · Reply
YPOJOB
YPOJOB Jun. 10 at 11:28 PM
$TXMD News????
0 · Reply
YPOJOB
YPOJOB Jun. 10 at 9:18 PM
$TXMD Nothing new here I guess. Just waiting. TXMD has products to sell. Which have been growing in sales. The only ones making money are the Lawyers. Big pet peeve of mine
0 · Reply
hiTHit
hiTHit Jun. 9 at 5:30 PM
$TXMD I didn't realize I was losing money here until my girlfriend told me she was breaking up with me because I had no money left.
0 · Reply
YPOJOB
YPOJOB Jun. 6 at 11:42 PM
$TXMD why sell now?
0 · Reply
JJYLT
JJYLT Jun. 6 at 6:29 PM
$TXMD 🌞 😎
0 · Reply